← Leaderboards
Yoon Yeo
Purdue University
$6,785,486
Attributed
$9,392,737
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,392,737 · 9
By mechanism
R01$7,554,840 · 4
T32$948,570 · 1
R21$790,298 · 2
R03$89,349 · 1
R13$9,680 · 1
Top collaborators
- Robert Virgil Stahelin5 shared
- Stephen J. Kron4 shared
- Timothy W Corson3 shared
- Anthony Brent Daniels1 shared
- Tao Lu1 shared
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventUnited States National Institutes Of HealthDrug Delivery SystemsMissionResourcesDrug KineticsHuman DiseaseTumorToxic EffectCancer TherapyNanoparticlePublic HealthResearch PersonnelNovel TherapeuticsNeoplastic CellBaseSurfaceNanomedicineTumor GrowthInnovationDoseBiodistributionChemotherapyPaclitaxel
Grant awards (29)
Long-acting formulations of griseofulvin for ocular neovascularization therapy$649,794
R01 · FY2025 · EY · contact PI
Improving the potency of novel PRMT5 inhibitor with nanocrystal technology to treat pancreatic cancer$89,349
R03 · FY2025 · CA
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer$559,672
R01 · FY2024 · CA · contact PI
Long-acting formulations of griseofulvin for ocular neovascularization therapy$513,683
R01 · FY2024 · EY · contact PI
Drug Discovery in Infectious Disease Training$180,646
T32 · FY2024 · AI
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer$576,966
R01 · FY2023 · CA · contact PI
Long-acting formulations of griseofulvin for ocular neovascularization therapy$523,302
R01 · FY2023 · EY
Drug Discovery in Infectious Disease Training$166,632
T32 · FY2023 · AI
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer$576,726
R01 · FY2022 · CA · contact PI
Chemotherapy delivery with nanoparticles for targeted induction of immunogenic cell death$399,806
R01 · FY2022 · CA · contact PI
Drug Discovery in Infectious Disease Training$207,370
T32 · FY2022 · AI
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer$602,006
R01 · FY2021 · CA · contact PI
Chemotherapy delivery with nanoparticles for targeted induction of immunogenic cell death$407,966
R01 · FY2021 · CA · contact PI
Drug Discovery in Infectious Disease Training$198,076
T32 · FY2021 · AI
Beyond Nano, Challenges and Opportunities In Drug Delivery$9,680
R13 · FY2021 · TR · contact PI
Chemotherapy delivery with nanoparticles for targeted induction of immunogenic cell death$407,966
R01 · FY2020 · CA · contact PI
Drug Discovery in Infectious Disease Training$195,846
T32 · FY2020 · AI
Chemotherapy delivery with nanoparticles for targeted induction of immunogenic cell death$409,064
R01 · FY2019 · CA · contact PI
Chemotherapy delivery with nanoparticles for targeted induction of immunogenic cell death$355,506
R01 · FY2018 · CA · contact PI
Environmentally-adaptive nanoparticles with focal irradiation for cancer therapy$142,517
R01 · FY2018 · EB · contact PI
Environmentally-adaptive nanoparticles with focal irradiation for cancer therapy$349,200
R01 · FY2017 · EB · contact PI
Environmentally-adaptive nanoparticles with focal irradiation for cancer therapy$27,900
R01 · FY2017 · EB · contact PI
Environmentally-adaptive nanoparticles with focal irradiation for cancer therapy$349,200
R01 · FY2016 · EB · contact PI
Polysaccharide-based endotoxin antagonist for the treatment of sepsis$232,500
R21 · FY2016 · AI · contact PI
Environmentally-adaptive nanoparticles with focal irradiation for cancer therapy$342,216
R01 · FY2015 · EB · contact PI
Polysaccharide-based endotoxin antagonist for the treatment of sepsis$193,750
R21 · FY2015 · AI · contact PI
Environmentally-adaptive nanoparticles with focal irradiation for cancer therapy$361,350
R01 · FY2014 · EB · contact PI
Peritumorally transformable nanoparticles for intraperitoneal chemotherapy of ova$197,922
R21 · FY2010 · CA · contact PI
Peritumorally transformable nanoparticles for intraperitoneal chemotherapy of ova$166,126
R21 · FY2009 · CA · contact PI